Equillium (NASDAQ:EQ) COO Christine Zedelmayer Sells 14,584 Shares

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 14,584 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $2.93, for a total value of $42,731.12. Following the transaction, the chief operating officer directly owned 62,586 shares of the company’s stock, valued at approximately $183,376.98. The trade was a 18.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Zedelmayer also recently made the following trade(s):

• On Thursday, May 28th, Christine Zedelmayer sold 86,012 shares of Equillium stock. The stock was sold at an average price of $2.80, for a total value of $240,833.60.
• On Wednesday, May 27th, Christine Zedelmayer sold 9,821 shares of Equillium stock. The stock was sold at an average price of $2.70, for a total value of $26,516.70.
• On Friday, March 13th, Christine Zedelmayer sold 120,312 shares of Equillium stock. The shares were sold at an average price of $2.50, for a total value of $300,780.00.
• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The shares were sold at an average price of $2.00, for a total value of $362,438.00.

Equillium Stock Performance

NASDAQ EQ opened at $2.94 on Friday. The business has a fifty day moving average price of $2.20 and a 200 day moving average price of $1.71. Equillium, Inc. has a one year low of $0.27 and a one year high of $3.45. The company has a market cap of $185.90 million, a P/E ratio of -9.19 and a beta of 1.77.

Equillium (NASDAQ:EQ) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). As a group, sell-side analysts predict that Equillium, Inc. will post -0.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Equillium

Several hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in Equillium by 10.8% during the 1st quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company’s stock worth $12,957,000 after acquiring an additional 632,359 shares in the last quarter. ADAR1 Capital Management LLC lifted its stake in Equillium by 0.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 5,608,078 shares of the company’s stock worth $8,693,000 after acquiring an additional 48,090 shares in the last quarter. Woodline Partners LP acquired a new position in Equillium during the 3rd quarter worth about $5,018,000. Aberdeen Group plc lifted its stake in Equillium by 523.6% during the 4th quarter. Aberdeen Group plc now owns 2,366,688 shares of the company’s stock worth $3,668,000 after acquiring an additional 1,987,162 shares in the last quarter. Finally, Balyasny Asset Management L.P. lifted its stake in Equillium by 3.6% during the 4th quarter. Balyasny Asset Management L.P. now owns 2,076,250 shares of the company’s stock worth $3,218,000 after acquiring an additional 72,602 shares in the last quarter. Institutional investors and hedge funds own 27.05% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Stifel Nicolaus set a $5.00 price objective on Equillium in a research note on Thursday, May 28th. Zacks Research raised Equillium to a “hold” rating in a research note on Thursday, February 26th. Leerink Partners raised Equillium from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $1.00 to $6.00 in a research note on Thursday, May 28th. Raymond James Financial reissued a “strong-buy” rating and issued a $7.00 price objective on shares of Equillium in a research note on Thursday, May 28th. Finally, Oppenheimer began coverage on Equillium in a report on Thursday, April 23rd. They issued an “outperform” rating and a $7.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Equillium has an average rating of “Moderate Buy” and a consensus target price of $7.57.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.